{"schema_version":"secwatch.filing_event.v1","accession":"0000947871-22-001199","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2022-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.269763+00:00","generated_at":"2026-06-21T15:21:32.418386+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CVS Health authorizes $10B share repurchase program; amends bylaws for universal proxy rules","bullets":["Board approved new $10B repurchase program after exhausting 2021 authorization.","Repurchases may occur via open market, private deals, accelerated share repurchase, or derivatives.","Bylaws amended to mandate compliance with SEC Rule 14a-19 for director nominations and proxies."],"urls":{"canonical":"https://secwatch.observer/filing/0000947871-22-001199","json":"https://secwatch.observer/filing/0000947871-22-001199.json","markdown":"https://secwatch.observer/filing/0000947871-22-001199.md","text":"https://secwatch.observer/filing/0000947871-22-001199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000094787122001199/0000947871-22-001199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000094787122001199/ss1535680_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:21:32.418386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91cf44587ba20f8f26986b600bce90618794a02f","claim":"CVS HEALTH Corp: Amended by-laws to revise Section 1.10 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-17).","evidence_excerpt":"On November 17, 2022, the Board of Directors of CVS Health Corporation (the “Company”) amended, effective immediately, the by-laws (the “By-laws”) of the Company to (a) revise Section 1.10 with respect to the notification and other requirements related to nominations of directors and solicitations of proxies, including requiring compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000094787122001199/0000947871-22-001199-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-11-17"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}